Breakthrough Alpha DaRT Discovered for Treatment of Recurrent GBM

Alpha Tau Medical discovered breakthrough Alpha DaRT to treat patients with recurrent glioblastoma multiform (GBM).

Alpha DaRT functions by inserting a seed into a cancerous tumor. The treatment is done by intratumoral insertion of radium-224 impregnated sources. This seed releases high energy alpha particles when radium decays thus destroying the tumor. Since the alpha-emitting atoms can only diffuse shorter distance, Alpha DaRT mainly affects the tumor leaving the healthy tissue around it.

Glioblastoma multiforme (GBM) is a brain tumor consisting of 5-year survival rate of less than 10%. It is the caused by common malignant tumor of the brain or central nervous system. GBM being the most serious disease, it is difficult to find new treatment for patients. Hence, GBM can be used as an adjunct to standard medical treatments or as a standalone therapy where no other standard medical therapies are working.

U.S. Food and Drug Administration (“FDA”) grants Breakthrough Device Designation for Alpha DaRT for the treatment of recurrent glioblastoma multiforme GBM.